Chiasma is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases by developing and commercializing oral medications that were previously available by injection only. The company's lead candidate is octreotide capsules, which has received orphan drug designation from the FDA and EMA.
Market
Rare diseases
Location
Newton Centre,
MA,
USA
Coinvestors
7 Med Health Ventures, Abingworth, ARCH Venture Partners, F2 Capital, MPM Capital, Rock Springs Capital, Sofinnova Ventures